Top

Our Science

Developing monoclonal antibody (mAb)
therapies for dogs and cats
THE IMPACT OF OUR MEDICATION

Working to improve the quality of life for dogs and cats with debilitating diseases

At VETmAb BIO, we are developing medications specifically designed for the species in which they will be used. Our scientists use multiple strategies to discover primary antibody leads with a balance of diversity and affinity. We create antibodies that are caninized (for dogs) or felinized (for cats). This process allows us to target diseases with a medication uniquely designed for our dog or cat family member.

The Monoclonal Antibody Discovery Process

1.
Our protein engineers design the antigens

2.
Lead discovery using multiple technologies

3.
Screen high-affinity binders with high potencies with functional assays

4.
Assess physical/chemical stability and antibody expressibility to reduce cost of goods

5.
Caninize or felinize IgG to reduce immunogenicity

6.
Assess early stage developability and manufacturability

7.
Develop proprietary Fc technology by modulating the Fc function and PK profile

Seperator Border

IN DEVELOPMENT

Prescription medications for dogs and cats with a focus on chronic diseases

VETmAb BIO scientists are pioneers in mAb technology with a proven track record. Our lead candidates are monoclonal antibodies and bispecific antibodies — a type of monoclonal antibody that has been engineered to bind to two different antigens by the same antibody — uniquely designed for use in dogs and cats. We are opening up new possibilities in treatment for a wide variety of diseases.

 

OPPORTUNITIES FOR PARTICIPATION

Sign your clinic up
for our clinical trials

COMING SOON

 

Seperator Border

STAY CONNECTED WITH US

Receive research updates, clinical trial information, and more.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.